Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute coronary syndromes

Treatment for low-risk patients with STEMI—challenges remain

Nature Reviews Cardiology volume 11, pages 440–442 (2014)Cite this article

Subjects

Mineralocorticoid-receptor antagonists (MRAs) have been shown to reduce adverse cardiovascular outcomes in high-risk patients with ST-segment elevation myocardial infarction (STEMI). Preliminary data suggest that MRAs might improve natriuretic-peptide profiles in patients with STEMI who do not have heart failure, but their clinical efficacy in this patient population requires further study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: MRAs have been shown to have a clinical benefit in patients with HF after STEMI, as well as in those with chronic HF with reduced ejection fraction and NYHA class II–IV symptoms.

References

  1. Steg, P. G. et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569–2619 (2012).

    Article  CAS  Google Scholar 

  2. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309–1321 (2003).

    Article  CAS  Google Scholar 

  3. Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).

    Article  CAS  Google Scholar 

  4. Montalescot, G. et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind REMINDER study. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu164.

  5. Fox, K. A. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 333, 1091 (2006).

    Article  Google Scholar 

  6. Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11–21 (2011).

    Article  CAS  Google Scholar 

  7. Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College Of Cardiology Foundation/American Heart Association Task Force On Practice Guidelines. J. Am. Coll. Cardiol. 15, e147–e239 (2013).

  8. Januzzi, J. L. & Troughton, R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation 127, 500–507 (2013).

    Article  Google Scholar 

  9. Felker, G. M. & Ahmad, T. Natriuretic peptides and primary prevention: the new world? J. Am. Coll. Cardiol. 62, 1373–1375 (2013).

    Article  Google Scholar 

  10. Rao, K. K. et al. Use of aldosterone antagonists at discharge after myocardial infarction: results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With The Guidelines (GWTG). Am. Heart J. 166, 709–715 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, 2400 Pratt Street, Durham, 27707, NC, USA

    Tariq Ahmad & Matthew T. Roe

Authors
  1. Tariq Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew T. Roe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew T. Roe.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmad, T., Roe, M. Treatment for low-risk patients with STEMI—challenges remain. Nat Rev Cardiol 11, 440–442 (2014). https://doi.org/10.1038/nrcardio.2014.89

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.89

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing